October Grants

Federal Grants

Altschuler, S., NIH, Turnkey Solution for Image Phenotype Classification, $225,000; Amatruda, J., NIH, Generation and Rapid Mapping of Low-Penetrance Disease Alleles in Zebrafish, $207,500; Brugarolas, J., NIH, Regulation of the mTOR Pathway by Hypoxia and the REDD1 Protein, $203,350; Buchanan, G., CDC/TKC Integration Services, Diamond Blackfan Anemia Education and Outreach Program, $62,377; Burgess, S., NIH/ Vanderbilt University Medical Center, Exercise and Fuel Metabolism, $21,250.

Byerly, M., NIH/Univ. of N.C. at Chapel Hill, Clinical Antipsychotic Trials of Intervention Effectiveness, $49,416; Cavanagh, D., NIH/Jaeb Center for Health Research, Cornea Donor Study, $3,460; Clegg, D., NIH/Purdue Univ., Energy Dysregulation: Behavioral and Biological Signals, $12,082; Dowling, M., NIH/ Washington University, Silent Cerebral Infarct Multi-Center Clinical Trial, $3,968; Freeman, A., DHHS/Univ. of Calif., A Community-Level HIV-Prevention Intervention for Young Black Men, $124,499.

Fu, Q., NIH, Hypertension and Antihypertensive Therapy in Elderly Women, $382,118; Gao, J., DOD, Ultrasensitive MRI Contrast Agents for Early Detection of Breast Cancer, $135,874 (Khemtong, C., fellow); Garcia-Martinez, J.V., NIH, Vaginal/Rectal HIV Transmission Model, $363,293; Garcia-Martinez, J.V., NIH, Implementation of a Vaginal/Rectal HIV Transmission Model to Evaluate Microbicides, $250,000; German, D., NIH/RJW Med. Sch., Adenosine, Glutamate and Neurodegeneration, $34,858.

Gruchalla, R., NIH/Univ. of Wis.–Madison, Correlation Between Serum IgE and the Capacity of Blood Dendritic Cells to Upregulate Surface MHC Class II Upon Viral Encounter, $78,420; Hennes, H., NIH, EMSC Targeted Issue Grants, $240,241; Hodics, T., NIH, TDCS-Enhanced Stroke Recovery and Cortical Reorganization, $150,300; Idris, A., AHA/Univ. of Wash., Resuscitation Outcome Consortium Registry, $46,993; Lai, H., NIH, Transcriptional Regulatory Control of Neuronal Cell Type Specification, $51,278.

Lee, W., NIH, A Multicenter Study of Acute Liver Failure in Adults, $664,743; Lee, W., NIH, UT Southwestern: Clinical Site for the Drug-Induced Liver Injury Network, $156,155; Lee, W., NIH, North Texas Hepatitis B Consortium: Clinical Site for the Hepatitis B Network, $113,313; Levine, B., NASA, Cardiac Atrophy and Diastolic Dysfunction During and After Duration Spaceflight, $159,282; Leveno, K., NIH, NICHD Maternal Fetal Medicine Units Network, $878,486.

Lu, H., NIH, Normalized Functional MRI in Human Brain Disorders, $240,568; MacDonald, R., NIH/Vanderbilt Univ. Med. Ctr., Resolution of Islet and Acinar Cell Lineages in Development, $234,337; McKnight, S., NIH/Mount Sinai School of Med., Neural Substrates of Appetitive Behavior in Mood and Motivation, $70,000; Minna, J., DOD/UT M.D. Anderson Cancer Ctr., Project 1B, $61,493; Minna, J., DOD/UT M.D. Anderson Cancer Ctr., Project 3A, $28,840.

Minna, J., NIH, UT SPORE in Lung Cancer, $1,900,438; Mohan, C., NIH/John Hopkins Univ. Sch. of Med., Hopkins Lupus Cohort, $9,540; North C., NIH, Psychoeducation of HCV and Alcohol Behaviors, $191,300; Olsen, N., NIH/ ArthroChip, Gene Expression and Diagnosis of Autoimmune Disease, $127,389; Olsen, N., NIH/Univ. of Calif., San Francisco, Collaborative Network for Clinical Research in Immune Tolerance, $120,044.

Otwinowski, Z., NIH/Northwestern Univ., Center for Structural Genomics of Infectious Diseases, $125,333; Parada, L., NIH/Mount Sinai Sch. of Med., Neural Substrates of Appetitive Behavior in Mood and Motivation, $40,000; Ramilo, O., HRSA, Ryan White Care Act Title IV Program, $74,960; Ramilo, O., HRSA, Ryan White Care Act Title IV Adolescent Initiative, $66,000; Ramilo, O., HRSA, Ryan White Care Act Title IV Adolescent Initiative, $58,350.

Ramilo, O., HRSA, Ryan White Care Act Title IV, $58,050; Schatzle, J., NIH/Moffitt Cancer Ctr., Role of SHIP in NK Cell Biology, $50,000; Scherer, P., NIH/ Children’s Hosp. Med. Ctr., Adiponectin and Cardiovascular Disease in the CKid Children, $45,675; Shay, J., NIH/Univ. of Neb. Med. Ctr., SPORE in Gastrointestinal Cancer, $74,893; Sun, X., NIH/Texas A&M Research Fndtn., Molecular Recognition in Dendrimers Based on Melamine, $63,735.

Van Oers, N., NIH, Integrative Immunology Training Program, $335,205; van Oers, N., NIH, CD3 E Functions in T Cells, $250,000; Vazquez, M., NIH, Anatomic and Functional Predictors of Arteriovenous Fistula Maturation, $225,000; Wakeland, E., NIH/Baylor Research Institute, Center for Lupus Research, $31,847; Winick, N., NIH/CureSearch – National Childhood Cancer Fndtn., Phase 1 Pilot Consortium Grant, $15,323.

Wright, W., NIH, T-Loop Dynamics During Tlomerase Inhibition Chemotherapy, $49,646 (Smiraldo, P., fellow); Yang, Y., NIH, PLAGL2 Expression in Emphysema Patient Lungs, $50,000; Yanagisawa, M., NIH/Mount Sinai Sch. of Med., Neural Substrates of Appetitive Behavior in Mood and Motivation, $70,000.

Nonfederal Grants

Castrillo, D., Amer. Cancer Soc., Genetic Model Systems and Translation Studies of Endometrial Cancer, $156,926; Eisch, A., Alberta Heritage Foundation for Medical Research, The Biochemical and Genetic Basis of Neuropsychiatric Disorders, $21,500 (Melvin, N., fellow); Joho, R., NARSAD, Kv3 Channels-Deficient Mice: A Model for Schizophrenia and Bipolar Disorder, $46,296; Lu, Q.R., Natl. Multiple Sclerosis Soc., Zfp488 in Oligodendrocyte Differentiation, $140,343.

Monson, N., Natl. Multiple Sclerosis Soc., Molecular Analysis of the Ig Repertoire in MS, $145,754; Olson, E., Foundation LeDucq, Micro RNAs as Therapeutic Targets in Heart Failure, $229,350; Parada, L., Simons Fndtn., Dysregulation of P13K/AKT Pathway: Mouse Models of Social Interaction Deficits and for ASD with Macrocephaly, $66,605; Parada, L., Amer. Cancer Soc., Modeling Tumors of the Nervous System, $80,000.

Stüve, O., Natl. Multiple Sclerosis Soc., The Role of Four Integrin Antagonism in CNS Autoimmune Disease, $40,000; Sun, X., UT Dallas/Juvenile Diabetes Research Fndtn., Noninvasive Imaging Pancreatic Beta Cells Using Novel GLP-1 Constructs, $135,800; Thomas, P., Cystic Fibrosis Fndtn. Therapeutics, Development of Methods and Reagents for Assessing CFTR Folding, $285,864; Willson, J., Amer. Cancer Soc., Institutional Research Grant, $150,000; Wright, T., ACR Research and Edu. Fndtn., Obesity and Insulin Resistance in Pediatric Systemic Lupus Erythematosus, $50,000.

Pharmaceutical studies, dollar amounts not available

Addo, T., A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Study Drug in Addition to Standard of Care in Subjects With Acute Coronary Syndrome: Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome; Arnold, S., Safety and Effectiveness of Open-Label Study Drug in Subjects With Lennox-Gastaut Syndrome; Chin, K., A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Crossover Study to Assess the Effects of a Single Dose of Study Drug on Exercise Capacity in Patients With Symptomatic Pulmonary Arterial Hypertension.

Chin, K., A Multicenter, Double-Blind, Randomized Study Comparing the Safety and Tolerability of Study Drug Inhalation Solution Delivered by I-neb Utilizing Power dis-15 and Power disc-6 in Patients With Symptomatic Pulmonary Arterial Hypertension; Gill, K., A Multicenter, Prospective, Randomized, Controlled Clinical Trial Comparing the Safety and Effectiveness of Study Device to Anterior Cervical Discectomy and Fusion Surgery in the Treatment of Symptomatic Cervical Disc Disease; Gill, K., A Multicenter, Prospective, Randomized, Controlled Clinical Trial Comparing the Safety and Effectiveness of Study Device to Anterior Cervical Discectomy and Fusion Surgery in the Treatment of Symptomatic Cervical Disc Disease – Continued Access Study Arm.

Lee, W., Use of Beckman Coulter’s Access Immunoassay System Assays for Hepatitis Viruses for the Diagnosis of Hepatitis Infection and Disease; Patel, A., A Multicenter, Prospective, Long-Term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease; Raskin, P., Feasibility of Finesse to Be as Effective and Safe but More Acceptable to Diabetes Patients Compared to Multiple Daily Injections With Pen Devices/ Syringes for Bolus Prandial Insulin Dosing.

Saxena, K., Evaluation of Study Drug as an Add-on Treatment for Bipolar I Disorder in Children and Adolescents, 10 to 17 Years of Age; Saxena, R., A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Study Drug for Prevention of Chronic Kidney Disease Progression in Patients With Moderate to Severe Chronic Kidney Disease Including Assessment of Quality of Life; Smith, S., Endurant Stent Graft System U.S. Clinical Study.

Swaroop, P., A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Investigate the Safety and Efficacy of Study Drug in Subjects With Moderate to Severe Crohn’s Disease; Verma, U., A Randomized Phase I/II Study With Gemcitabine and Study Drug or Gemcitabine and Placebo for Patients With Unresectable Pancreatic Cancer; Weiner, M., Open-Label Extension Study of Study Drug in Patients With Moderate to Severe Alzheimer’s Disease.


Share: